Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772420 | 1.00 | ELANE (0.65) | ELANEALDH1A1CA12CA9MAPT | |
| SCHEMBL11870038 | 0.86 | ELANE (0.61) | ELANEALDH1A1CA12CA9MAPT | |
| SCHEMBL11871329 | 0.86 | ELANE (0.70) | ELANEALDH1A1CA12CA9MAPT | |
| SCHEMBL11867108 | 0.83 | ELANE (0.58) | ELANEALDH1A1CA12CA9MAPT | |
| Ethylene SCHEMBL11863886 | 0.83 | ELANE (0.67) | ELANEALDH1A1CA12CA9MAPT | |
| SCHEMBL11509522 | 0.83 | ALDH1A1 (0.60) | ELANEALDH1A1CA12CA9MAPT | |
| SCHEMBL11509296 | 0.82 | ELANE (0.57) | ELANEALDH1A1CA12CA9MAPT | |
| Ethylene SCHEMBL11865796 | 0.80 | ELANE (0.56) | ELANEALDH1A1CA12CA9MAPT | |
| SCHEMBL12902033 | 0.80 | ELANE (0.56) | ELANEALDH1A1CA12CA9MAPT | |
| SCHEMBL2253697 | 0.79 | CA12 (0.58) | ELANEALDH1A1CA12CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473295-B2 | Substituted straight chain spiro derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| CN-118344372-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118255774-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118255773-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4268824-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Manros Therapeutics (FR) | 2023-11-01 | — | — | EP | disclosed |
| EP-4268824-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Manros Therapeutics (FR) | 2023-11-01 | — | — | EP | disclosed |
| US-20230142285-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230142285-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230142285-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| CN-114867721-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7550501-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550501-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7202234-B2 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | ELANE 109/4885ALDH1A1 2369/4885CA12 3183/4885 |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | TLR2, TLR6, TLR3 | ELANE 451/4885ALDH1A1 1679/4885CA12 2112/4885 |
| US-12473295-B2 | Substituted straight chain spiro derivatives | MLLT1, MEN1, MLLT3 | ELANE 3988/4885ALDH1A1 2388/4885CA12 4845/4885 |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | ELANE 451/4885ALDH1A1 1679/4885CA12 2112/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | ELANE 109/4885ALDH1A1 2369/4885CA12 3183/4885 |
| US-20230142285-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | MLLT1, MEN1, MLLT3 | ELANE 3988/4885ALDH1A1 2388/4885CA12 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.